Service de Transplantation, Néphrologie et Immunologie Clinique, Hôpital Edouard Herriot, Lyon, France.
Research on Healthcare Performance RESHAPE, INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.
Rheumatology (Oxford). 2024 Mar 1;63(3):780-786. doi: 10.1093/rheumatology/kead293.
Lupus activity has long been considered to decline after initiation of maintenance dialysis (MD). This assumption is based on limited historical data. We aimed to describe the natural history of lupus in patients undergoing MD.
We assembled a national retrospective cohort of lupus patients who started dialysis between 2008 and 2011, included in the REIN registry with a 5-year follow-up. We analysed healthcare consumption from the National Health Data System. We evaluated the proportion of patients 'off-treatment' (i.e. receiving 0-5 mg/d of corticosteroids, without any immunosuppressive therapy) after the start of MD. We describe the cumulative incidences of non-severe and severe lupus flares, cardiovascular events, severe infections, kidney transplantation and survival.
We included 137 patients (121 females and 16 males), with a median age of 42 years. The proportion of patients 'off-treatment' at dialysis initiation was 67.7% (95% CI: 61.8, 73.8%), and increased to 76.0% (95% CI: 73.3, 78.8) at 1 year and 83.4% (95% CI: 81.0, 85.9%) at 3 years, with a lower proportion in younger patients. Lupus flares mainly occurred in the first year after MD initiation, and at 12 months 51.6% of patients had presented a non-severe lupus flare and 11.6% a severe lupus flare. In addition, 42.2% (95% CI: 32.9, 50.3%) and 23.7% (95% CI: 16.0, 30.7%) of patients at 12 months had been hospitalized for cardiovascular events or infections, respectively.
The proportion of lupus patients off-treatment increases after MD initiation, but non-severe and severe lupus flares continue to occur, mainly during the first year. This calls for the continued follow-up of lupus patients by lupus specialists after dialysis initiation.
长期以来,人们一直认为狼疮在开始维持性透析(MD)后会减轻。这一假设基于有限的历史数据。我们旨在描述正在接受 MD 的患者中狼疮的自然史。
我们组建了一个全国性的回顾性队列,纳入了 2008 年至 2011 年间开始透析且随访时间达 5 年的狼疮患者。我们从国家健康数据系统分析了医疗保健的使用情况。评估了 MD 开始后接受 0-5mg/d 皮质类固醇治疗(即接受任何免疫抑制治疗)的患者比例。我们描述了非严重和严重狼疮发作、心血管事件、严重感染、肾移植和生存率的累积发生率。
我们纳入了 137 名患者(121 名女性和 16 名男性),中位年龄为 42 岁。透析起始时无治疗的患者比例为 67.7%(95%CI:61.8,73.8%),1 年后增至 76.0%(95%CI:73.3,78.8%),3 年后增至 83.4%(95%CI:81.0,85.9%),年轻患者的比例较低。狼疮发作主要发生在 MD 起始后的第一年,12 个月时 51.6%的患者出现非严重狼疮发作,11.6%的患者出现严重狼疮发作。此外,12 个月时 42.2%(95%CI:32.9,50.3%)和 23.7%(95%CI:16.0,30.7%)的患者因心血管事件或感染住院治疗。
MD 起始后,无治疗的狼疮患者比例增加,但非严重和严重狼疮发作仍持续发生,主要发生在第一年。这呼吁在透析起始后由狼疮专家继续对狼疮患者进行随访。